Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Suggested remit: To appraise the clinical and cost effectiveness of insulin icodec within its marketing authorisation for treating type 2 diabetes. Following an update from the company (Novo Nordisk), ...

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. | The FDA issued a ...

The FDA sent the Danish drugmaker a complete response letter (CRL) declining to approve the drug, insulin icodec, saying that it needs more information on its manufacturing process, as well as ...

insulin icodec, that we hope will reduce the disease burden even further. “Beyond this, we also aim to develop a glucose-sensitive insulin, which would only be activated in the body of the ...

USA: A recent analysis from the ONWARDS clinical trials has revealed significant improvements in treatment satisfaction among individuals with Type 2 diabetes using once-weekly insulin icodec compared ...

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] Technology appraisal guidance 30 April 2025 Lorlatinib ...

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Novo Nordisk A/S (NVO) ...

Compared with once-daily insulin, insulin icodec was linked to significant reductions in HbA 1c (MD, -0.21; 95% CI, -0.38 to -0.03) but basal insulin was not. Multitarget strategies involving ...

Medscape Medical News, September 17, 2024 EASD 2024 Icodec + Semaglutide Combo Shows Benefit in Type 2 Diabetes Combination may offer a substitute to basal-bolus insulin in people with type 2 ...